The rise in prevalence of target diseases and rising demand for cancer therapeutics worldwide are boosting the global nuclear medicine market predicts Fortune Business Insights in their recent study. The study is titled “Nuclear Medicine Market Size, Share and Global Trend By Type (Diagnostic, Therapeutics), By Application (Cancer, Cardiovascular diseases, Neurological disorder, Gastrointestinal diseases, Others), By End User (Diagnostic laboratories, Hospitals, Ambulatory services, Others) and Geography Forecast till 2026,” and it covers several important aspects related to the market including drivers, restraints, trends and opportunities, and offers insights into key strategies adopted by market vendors to stay ahead in competition.
Get Sample PDF Brochure @
Rise in Prevalence of Cancer Worldwide to Promote Growth of Radiopharmaceuticals
One of the major factors propelling the global nuclear medicine market growth is the rising prevalence of various types of cancer worldwide. The World Health Organization states that cancer ranks second in terms of deaths worldwide, and accounted for about 8.8million deaths in 2015. This rise has a direct impact on the use of nuclear medicines or radiopharmaceuticals and will help the market generate higher revenues in the forecast period.
Other factors promoting the enabling global nuclear medicine market growth is advancement in treatment monitoring, and wide adoption of Position Emission Tomography (PET) tools for medication. They are gaining much more traction in the market owing to the fact that PET tools has higher precision over other treatment procedures.
Browse Complete Report Details @
- Cardiovascular diseases
- Neurological disorder
- Gastrointestinal diseases
By End User
- Diagnostic laboratories
- Ambulatory services
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Some of the Main Key Players Covered in the Report
- General Electric Company
- Mallinckrodt plc
- Eckert & Ziegler Strahlen- und Medizintechnik AG
- Teva Pharmaceutical Industries Ltd
- Jubilant Life Sciences Ltd.
More Trending Topics from Fortune Business Insights: